Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gushukang capsules for primary osteoporosis
ChiCTR2200065196Phase 4Not yet recruiting
- Sponsor
- 中国中医科学院望京医院
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Gushukang in involutional osteoporosis (2 arms), sponsored by 中国中医科学院望京医院. Primary endpoint: Bone mineral density. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Gushukang
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on ChiCTR2200065196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065196.